| Similar Articles |
|---|
 |
BusinessWeek
January 19, 2004 |
Sniffing For Anthrax Little-known Cepheid has caught the eye not only of traders but also of long-term big investors.   |
The Motley Fool
November 8, 2007
Brian Orelli |
The 2 Sides of Bio-Rad Results for the third quarter reflect stellar clinical sales combined with mediocre laboratory sales. |
Chemistry World
September 4, 2015
Matthew Gunther |
US regulator reprimands Cepheid for norovirus diagnosis tool quality The US Food and Drug Administration has admonished the molecular diagnostics company Cepheid for failing to maintain good manufacturing practices. |
The Motley Fool
January 26, 2010
Dave Mock |
A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
Bio-IT World
November 14, 2003
Elizabeth Gardner |
Ultimate Analysis With the necessary tools at hand, the race is on to build -- and market -- the first affordable, portable, fully functional DNA analyzer. Is the world ready? |
Bio-IT World
January 21, 2005
Kevin Davies |
A Vision for iScience Applied Biosystems president Catherine Burzik discusses integrated science, lab technology, and running a $2B business. |
Chemistry World
October 29, 2015
Anthony King |
Poor diagnostics hinder battle against antibiotic resistance The tools used to diagnose bacterial infections have barely improved since the 1940s. |
Bio-IT World
March 10, 2003
Spink & Blumenstiel |
Getting IT Right Applying information technology to trials can boost productivity. Here's a strategic framework for going e-clinical. |
Bio-IT World
Jul/Aug 2006
Robert M. Frederickson |
Tests for Hospital-Acquired Infections Tests for pathogens increasingly rely on genomic methods that identify specific genetic signatures of bacteria or viruses. Rapid detection of other pathogens also provides the potential for significant impact on the healthcare industry. |
Bio-IT World
August 2005
Ellen H. Julian |
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. |
Pharmaceutical Executive
September 1, 2013
Jill Wechsler |
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies. |
The Motley Fool
February 22, 2011
Ryan McBride |
Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs. |
